Palvella Therapeutics (PVLA) Accounts Payables (2013 - 2026)

Palvella Therapeutics (PVLA) has reported Accounts Payables for 14 consecutive years, with $5.4 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Accounts Payables rose 22.56% year-over-year to $5.4 million; the TTM figure through Mar 2026 stood at $5.4 million (up 22.56% YoY), while the FY2025 annual figure was $4.6 million, changed 0.2% from the prior year.
• Accounts Payables improved to $5.4 million in Q1 2026 per PVLA's latest filing, from $4.6 million in the prior quarter.
• Across five years, Accounts Payables topped out at $7.6 million in Q2 2023 and bottomed at $801000.0 in Q3 2024.
• Historically, Accounts Payables has averaged $3.6 million across 5 years, with a median of $4.2 million in 2022.
• On a YoY basis, Accounts Payables climbed as much as 389.96% in 2024 and fell as far as 87.26% in 2024.
• Palvella Therapeutics' Accounts Payables stood at $4.2 million in 2022, then plunged by 77.47% to $936000.0 in 2023, then soared by 389.96% to $4.6 million in 2024, then climbed by 0.2% to $4.6 million in 2025, then grew by 18.45% to $5.4 million in 2026.
• Business Quant data shows PVLA's Accounts Payables at $5.4 million in Q1 2026, $4.6 million in Q4 2025, and $3.5 million in Q3 2025.